Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4146511 | 0.82 | LMNA (0.44) | PGRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4148107 | 0.81 | HPGD (0.47) | MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL4146476 | 0.80 | CSNK1D (0.41) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL4144971 | 0.78 | MEN1 (0.42) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL9949807 | 0.77 | MAPK14 (0.55) | MAPTDRD2HTR2AHTR2CMEN1 | |
| SCHEMBL4143949 | 0.77 | LMNA (0.46) | MAPTMEN1KMT2ANPC1GSK3A | |
| SCHEMBL4137113 | 0.75 | AR (0.60) | PGRMAPTMMP2MMP9MMP8 | |
| SCHEMBL4145440 | 0.75 | TNKS2 (0.47) | MAPT | |
| SCHEMBL4140138 | 0.75 | KIF11 (0.44) | MAPTMEN1KMT2AGSK3AGSK3B | |
| SCHEMBL4144687 | 0.73 | AR (0.46) | MAPTDRD2HTR2AHTR2CGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891067-B1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-8580811-B2 | Androgen receptor modulator methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120165362-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165362-A1 | Androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | PGR 43/4885MAPT 4308/4885MMP2 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.